

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.


For additional information about this publication click this link.

<http://hdl.handle.net/2066/193413>

Please be advised that this information was generated on 2019-04-22 and may be subject to change.

Editorial

Special Issue Introduction: Inherited Retinal Disease: Novel Candidate Genes, Genotype–Phenotype Correlations, and Inheritance Models

Frans P. M. Cremers ^{1,*}, Camiel J. F. Boon ^{2,3}, Kinga Bujakowska ⁴ and Christina Zeitz ^{5,*} 

¹ Department of Human Genetics and Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

² Department of Ophthalmology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands; C.J.F.Boon@lumc.nl

³ Academic Medical Center, Department of Ophthalmology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

⁴ Ocular Genomics Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA; Kinga_Bujakowska@MEEI.HARVARD.EDU

⁵ Sorbonne Université, INSERM, CNRS, Institut de la Vision, Department of Genetics, 17 rue Moreau, 75012 Paris, France

* Correspondence: Frans.Cremers@radboudumc.nl (F.P.M.C.); christina.zeitz@inserm.fr (C.Z.)

Received: 5 April 2018; Accepted: 13 April 2018; Published: 16 April 2018



Inherited retinal diseases (IRDs) are genetically and clinically heterogeneous disorders. Together, they have an estimated incidence of 1:2000 and thereby are the leading cause of vision loss in persons between 15 and 45 years of age [1–3]. IRDs can be clinically classified based on disease progression and the retinal cell types that are primarily involved in disease pathogenesis. They can be stationary, as for instance observed in most cases with congenital stationary night blindness (CSNB) and achromatopsia (ACHM), or progressive, such as in retinitis pigmentosa (RP), which is basically a rod-cone dystrophy, but also in cone-rod dystrophy (CRD) and Stargardt disease (STGD1). A second classification is based on the primary dysfunction or degeneration of the rod or cone photoreceptor cells. We can distinguish CSNB, which represents a dysfunction of retinal signaling from rods and cones to bipolar cells [4], and ACHM, or color blindness [5], in which one or more of the three types of cone cells are dysfunctional. In persons with CRD and STGD1, cones are affected first, followed by the degeneration of rods. This means that affected individuals initially experience central vision defects, which expand towards the mid-periphery. In persons with RP, this is the converse: initial clinical symptoms are night blindness and tunnel vision due to rod degeneration; central vision can also become impaired with progressive disease when cones also degenerate, eventually leading to legal blindness. Late in the disease process, both cones and rods are affected in CRD, RP, and STGD1, which make it difficult to come to a clear diagnosis. The most severe form of IRD is Leber congenital amaurosis (LCA), in which not only cones and rods of the neural retina can be affected simultaneously, but in which the retinal pigment epithelium (RPE) can also be primarily involved [6,7].

A few phenotypes, such as choroideremia (CHM) and STGD1, are caused by mutations in single genes, *CHM* and *ABCA4*, respectively [8,9]. In most of the IRDs, mutations in many different genes can cause very similar phenotypes. For example, mutations in 84 different genes underlie RP [10], 33 genes are implicated in cone dystrophy (CD)/CRD, 20 genes are involved in macular dystrophies (MD), 15 genes are involved in CSNB, and 9 genes are mutated in familial exudative vitreoretinopathy (FEVR) (Figure 1) [11].




Figure 1. Genetic heterogeneity among the six major non-syndromic inherited retinal diseases (IRDs). Numbers outside of the ellipses correspond to the number of non-syndromic IRD genes responsible for the specific disease, while numbers within the ellipses correspond either to disease-specific genes or to genes mutated in two or more diseases. The non-redundant total of genes associated with these non-syndromic IRDs is 146. RP: retinitis pigmentosa; LCA: Leber congenital amaurosis; CD/CRD: cone dystrophy/cone-rod dystrophy; CSNB: congenital stationary night blindness; MD: macular dystrophy; EVR: exudative vitreoretinopathy.

Different variants in one gene can cause autosomal recessive (ar) or dominant (ad) retinal dystrophies (RDs), as exemplified by *GUCY2D* in which ad variants result in CRD and ar variants cause LCA [12,13]. Similarly, variants in rhodopsin (*RHO*) and *RP1* can be involved in adRP and arRP [14–17]. Although many arRDs are caused by mutations that result in the absence of functional protein, there are also several examples in which there is residual protein activity. Different combinations of mutations in some genes thereby can be associated with IRDs with different severity. For example, two null alleles in *ABCA4* result in early-onset CRD, whereas combinations of severe and mild variants result in intermediate or late-onset STGD1 [9,18–21]. Different combinations of mutations in the same gene can also cause syndromic and non-syndromic forms of arRDs. Some *USH2A* mutations either cause non-syndromic arRP or Usher syndrome type 2 [22,23]. Mutations in Bardet–Biedl syndrome (BBS)-associated genes, such as *BBS1*, can also be found in non-syndromic arRP [24–26], and *CEP290* variants underlie LCA, Senior–Løken syndrome, Joubert syndrome, or Meckel–Gruber syndrome [27–30]. Finally, bi-allelic null mutations in some IRD-associated genes may be lethal. The far majority of LCA cases carrying *NMNAT1* variants carry one hypomorphic variant and one null allele [31–35], and it was hypothesized that two *NMNAT1* null alleles could be lethal [35] or are associated with syndromic IRD.

The first retinal disease-associated gene identified was the ornithine aminotransferase (*OAT*) gene involved in gyrate atrophy. Reduced ornithine aminotransferase activity was measured in a patient’s cells in 1977 [36], and in 1988, the *OAT* gene was cloned, and the first mutation was identified [37]. Two years later, the second and third IRD-associated genes were identified. Mutations in the *RHO* gene, encoding the rod-specific light-sensitive chromophore, were identified in patients with adRP using a candidate gene approach [14] after linkage analysis in a large Irish adRP family had pointed towards a genomic region encompassing this gene [38]. In the same year, the *CHM* gene was identified using a positional cloning approach by mapping deletions in patients with syndromic and non-syndromic choroideremia [8].

The candidate gene approach (i.e., the search for IRD-associated variants in genes encoding proteins with known crucial functions in the retina) has been very successful. Similarly, comparing phenotypes of existing animal models with a known gene defect and subsequent screening of the respective candidate gene has identified many genes underlying IRD [4]. The identification of IRD-associated genes through their genomic position (i.e., positional cloning) as determined by linkage

analysis has been used effectively, though this generally requires the availability of large families or a large set of families in which the same locus is involved. Linkage studies can be performed using microarrays that test thousands of single nucleotide polymorphisms (SNPs) spread across the genome. SNP microarrays have also proven very valuable for homozygosity and identity-by-descent (IBD) mapping of recessive disease genes, not only in consanguineous families [27,39], but also in small families and single patients of non-consanguineous marriages [40,41]. We are witnessing a new era in disease gene identification with the introduction of next-generation sequencing, allowing the analysis of all genes implicated in IRD [42] in a defined linkage interval, all exons in the genome (whole exome sequencing (WES)) [43–46], or even the entire genomic sequence (whole genome sequencing (WGS)) [47]. This also brings new challenges, such as data analysis and interpretation of genomic variants. Given the huge number of variants present in a patient's genome, positional information on where the causative gene may be localized (e.g., by linkage analysis and/or homozygosity mapping) remains very helpful to pinpoint the genetic defect. Employing WGS, thousands of rare single nucleotide variants (SNVs) and structural variations (SVs) are found in every individual, and it remains very challenging to identify the causal variant(s). A functional read-out is required to identify the culprit variant(s). Gene-specific mRNA analysis or genome-wide mRNA analysis (transcriptome analysis) may identify quantitative or structural defects in mRNAs.

Whole exome sequencing and gene-panel sequencing analysis genetically solve 55–60% of these cases [42,48–50]. The hidden genetic variations may be unrecognized SVs and deep-intronic variations, which can be identified by WGS or gene-specific locus sequencing. Copy number variations (CNV)s can explain up to 18% of previously unsolved cases [51,52].

Receiving a molecular diagnosis becomes increasingly important with the development of (gene) therapy for IRDs. Up to 10 years ago, it was not possible to slow down, stabilize, or treat the vision impairment in patients with IRDs. This changed for a small group of patients with *RPE65* mutations, as gene augmentation was successfully and safely applied through subretinal injections of recombinant adeno-associated viruses (rAAVs) in Phase 1/2 trials [53–55]. Recombinant adeno-associated viruses transduce the RPE cells, upon which the viruses are shuttled to the nucleus, and the rAAV vector remains a stable extrachromosomal element. In the meantime, many more patients have been treated in two centers in Philadelphia and one in London. Vision improvement was variable and, in general, modest and appears to be more effective in younger patients. A Phase 3 trial was conducted in one center using an improved rAAV vector, which resulted in increased subjective and objective vision in the treated eye versus the untreated eye [56]. Gene therapy for *RPE65*—associated with LCA or RP—in the form of Luxturna is now an approved treatment in the United States (U.S. Food and Drug Administration STN: 125610). Gene augmentation targeting photoreceptors and the RPE was also successfully performed in a Phase 1/2 trial in choroideremia patients [57,58]. In addition, an oral 9-*cis* retinoid supplementation therapy seems effective in patients with *RPE65* and *LRAT* mutations [59,60]. Several therapies that will be developed in the next years will be gene-, or even mutation-specific, emphasizing the importance for patients to receive a molecular diagnosis. An overview of all ongoing gene therapy trials can be found on the internet [61].

Proving the involvement of a gene defect in an IRD and often a definite genetic diagnosis are dependent on modeling of the identified mutation(s) in animals or in ex vivo assays. Defects in several genes were previously found as naturally occurring or were modeled in rodents, zebrafish, and *Drosophila* [62] (and references therein). Human mutations have also been modeled by over-expression of wild-type and mutant proteins with a presumed dominant effect in cell culture [63]. More sophisticated approaches have been developed to study potential splicing alterations or hypomorphic alleles [64,65]. Some assays can be performed directly in cells available from patients [27]. However, in the absence of patients' somatic cells that express the gene of interest, robust in vitro RNA splice assays can be set up for every human gene. In case retina-specific splice defects could play a role, photoreceptor precursor cells can be derived from induced pluripotent stem cells generated from blood cells or fibroblasts [66–71]. In addition to the new functional assays, the recent entrance of

CRISPR/Cas opens great opportunities for IRD research, as it enables a more efficient introduction of specific mutations into animal models or cells [72]. This technology also offers a new therapeutic potential [73].

Only a few examples of digenic inheritance and modifier genes for IRDs have been reported [74–78]. Nevertheless, there are many examples of significant differences between phenotypes (e.g., age at onset) in IRD cases that carry the same mutation(s), both within and between families. Reduced penetrance of variants might explain several autosomal dominant conditions, but as yet we have few clues regarding the genetic and possibly non-genetic modifiers. To study the mechanism of variable expression and non-penetrance, large case/control cohorts and genome-wide analysis techniques, such as WES and WGS, are required.

What are the future challenges in IRD research and diagnostics?

1. How can we determine causality for ultra-rare mutations in novel candidate genes? Apart from *in silico* tools that predict the potential causality of rare variants, we need to share our findings in a global manner. Tools for this are GeneMatcher [79,80] and intense collaborations, such as the European Retinal Disease Consortium (ERDC) [81].
2. How can we identify and functionally test non-coding variants?
3. To fully understand genotype–phenotype correlations, what are the effects of coding variants on RNA splicing and protein function?
4. Can we begin to understand phenotypic differences (and non-penetrance) of persons with the same mutations or the same types of mutations due to *cis* and *trans* modifiers or digenic inheritance?

With this special issue of the journal *Genes*, we address all the challenges mentioned above, except for the identification and functional testing of non-coding variants. In the paper by Astuti et al. [82] several probands carrying ultra-rare defects are presented in 11 novel candidate IRD genes through a European collaboration. The high aggregate carrier frequency of autosomal recessive variants associated with retinal dystrophies (up to 15%) [83] in some families with multiple affected individuals can result in the identification of independently acting defects in different genes, as shown by Gustafson et al. [84]. Llavona et al. [85] report on allelic mRNA imbalances for selected IRD-associated genes, which is very relevant to understanding phenotypic differences between individuals carrying the same genetic defects. El Shamieh et al. [86] report on additional RP-associated mutations in *KIZ*, encoding a ciliary protein, and the need to establish retina organoids from patient-derived iPS cells to understand the effect of these mutations on ciliary structure. The remaining nine manuscripts deal with genotype–phenotype correlations. They range from very large genotyping studies (e.g., the Target5000 study by Dockery et al. [87]) to targeted genotyping studies in pericentral RP (Comander et al. [88]) and early-onset RP and LCA families (Di Iorio et al. [89] and Porto et al. [90]). Brandl et al. [91] studied two genes encoding homologous proteins (IMPG1 and IMPG2) that are mutated in vitelliform macular dystrophies. Gene-specific studies were reported by McGuigan et al. (*EYS*—arRP) [92], Roosing et al. (*CEP290*—oligocone trichromacy) [93], Tracawska-Siemiątkowska et al. (*YARS*—RP, deafness, agenesis of the corpus callosum, and liver disease) [94], and Littink et al. (*NRL*—enhanced S-cone syndrome) [95].

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Rattner, A.; Sun, H.; Nathans, J. Molecular genetics of human retinal disease. *Annu. Rev. Genet.* **1999**, *33*, 89–131. [[CrossRef](#)] [[PubMed](#)]
2. Hamel, C. Retinitis pigmentosa. *Orphanet J. Rare Dis.* **2006**, *1*, 40. [[CrossRef](#)] [[PubMed](#)]

3. Krumpaszky, H.G.; Ludtke, R.; Mickler, A.; Klauss, V.; Selbmann, H.K. Blindness incidence in Germany. A population-based study from Württemberg-Hohenzollern. *Ophthalmologica* **1999**, *213*, 176–182. [[CrossRef](#)] [[PubMed](#)]
4. Zeitz, C.; Robson, A.G.; Audo, I. Congenital stationary night blindness: An analysis and update of genotype-phenotype correlations and pathogenic mechanisms. *Prog. Retin. Eye Res.* **2015**, *45*, 58–110. [[CrossRef](#)] [[PubMed](#)]
5. Hofmann, L.; Palczewski, K. Advances in understanding the molecular basis of the first steps in color vision. *Prog. Retin. Eye Res.* **2015**, *49*, 46–66. [[CrossRef](#)] [[PubMed](#)]
6. Den Hollander, A.I.; Black, A.; Bennett, J.; Cremers, F.P. Lighting a candle in the dark: Advances in genetics and gene therapy of recessive retinal dystrophies. *J. Clin. Investig.* **2010**, *120*, 3042–3053. [[CrossRef](#)] [[PubMed](#)]
7. Roosing, S.; Thiadens, A.A.; Hoyng, C.B.; Klaver, C.C.; den Hollander, A.I.; Cremers, F.P. Causes and consequences of inherited cone disorders. *Prog. Retin. Eye Res.* **2014**, *42*, 1–26. [[CrossRef](#)] [[PubMed](#)]
8. Cremers, F.P.; van de Pol, D.J.; van Kerkhoff, L.P.; Wieringa, B.; Ropers, H.H. Cloning of a gene that is rearranged in patients with choroideraemia. *Nature* **1990**, *347*, 674–677. [[CrossRef](#)] [[PubMed](#)]
9. Allikmets, R.; Singh, N.; Sun, H.; Shroyer, N.F.; Hutchinson, A.; Chidambaram, A.; Gerrard, B.; Baird, L.; Stauffer, D.; Peiffer, A.; et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive stargardt macular dystrophy. *Nat. Genet.* **1997**, *15*, 236–246. [[CrossRef](#)] [[PubMed](#)]
10. Verbakel, S.K.; van Huet, R.A.C.; Boon, C.J.F.; den Hollander, A.I.; Collin, R.W.J.; Klaver, C.C.W.; Hoyng, C.B.; Roepman, R.; Klevering, B.J. Non-syndromic retinitis pigmentosa. *Prog. Retin. Eye Res.* **2018**, in press. [[CrossRef](#)] [[PubMed](#)]
11. RetNet. Available online: <http://www.sph.uth.tmc.edu/RetNet/> (accessed on 17 March 2018).
12. Kelsell, R.E.; Gregory-Evans, K.; Payne, A.M.; Perrault, I.; Kaplan, J.; Yang, R.B.; Garbers, D.L.; Bird, A.C.; Moore, A.T.; Hunt, D.M. Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy. *Hum. Mol. Genet.* **1998**, *7*, 1179–1184. [[CrossRef](#)] [[PubMed](#)]
13. Perrault, I.; Rozet, J.M.; Calvas, P.; Gerber, S.; Camuzat, A.; Dollfus, H.; Chatelin, S.; Souied, E.; Ghazi, I.; Leowski, C.; et al. Retinal-specific guanylate cyclase gene mutations in Leber’s congenital amaurosis. *Nat. Genet.* **1996**, *14*, 461–464. [[CrossRef](#)] [[PubMed](#)]
14. Dryja, T.P.; McGee, T.L.; Reichel, E.; Hahn, L.B.; Cowley, G.S.; Yandell, D.W.; Sandberg, M.A.; Berson, E.L. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. *Nature* **1990**, *343*, 364–366. [[CrossRef](#)] [[PubMed](#)]
15. Rosenfeld, P.J.; Cowley, G.S.; McGee, T.L.; Sandberg, M.A.; Berson, E.L.; Dryja, T.P. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. *Nat. Genet.* **1992**, *1*, 209–213. [[CrossRef](#)] [[PubMed](#)]
16. Sullivan, L.S.; Heckenlively, J.R.; Bowne, S.J.; Zuo, J.; Hide, W.A.; Gal, A.; Denton, M.; Inglehearn, C.F.; Blanton, S.H.; Daiger, S.P. Mutations in a novel retina-specific gene cause autosomal dominant retinitis pigmentosa. *Nat. Genet.* **1999**, *22*, 255–259. [[CrossRef](#)] [[PubMed](#)]
17. Khaliq, S.; Abid, A.; Ismail, M.; Hameed, A.; Mohyuddin, A.; Lall, P.; Aziz, A.; Anwar, K.; Mehdi, S.Q. Novel association of *RP1* gene mutations with autosomal recessive retinitis pigmentosa. *J. Med. Genet.* **2005**, *42*, 436–438. [[CrossRef](#)] [[PubMed](#)]
18. Cremers, F.P.; van de Pol, D.J.; van Driel, M.; den Hollander, A.I.; van Haren, F.J.; Knoers, N.V.; Tijmes, N.; Bergen, A.A.; Rohrschneider, K.; Blankenagel, A.; et al. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site mutations in the Stargardt’s disease gene *ABCR*. *Hum. Mol. Genet.* **1998**, *7*, 355–362. [[CrossRef](#)] [[PubMed](#)]
19. Maugeri, A.; Klevering, B.J.; Rohrschneider, K.; Blankenagel, A.; Brunner, H.G.; Deutman, A.F.; Hoyng, C.B.; Cremers, F.P.M. Mutations in the *ABCA4* (*ABCR*) gene are the major cause of autosomal recessive cone-rod dystrophy. *Am. J. Hum. Genet.* **2000**, *67*, 960–966. [[CrossRef](#)] [[PubMed](#)]
20. Westeneng-van Haaften, S.C.; Boon, C.J.; Cremers, F.P.; Hoefsloot, L.H.; den Hollander, A.I.; Hoyng, C.B. Clinical and genetic characteristics of late-onset Stargardt’s disease. *Ophthalmology* **2012**, *119*, 1199–1210. [[CrossRef](#)] [[PubMed](#)]
21. Zernant, J.; Lee, W.; Collison, F.T.; Fishman, G.A.; Sergeev, Y.V.; Schuerch, K.; Sparrow, J.R.; Tsang, S.H.; Allikmets, R. Frequent hypomorphic alleles account for a significant fraction of *ABCA4* disease and distinguish it from age-related macular degeneration. *J. Med. Genet.* **2017**, *54*, 404–412. [[CrossRef](#)] [[PubMed](#)]

22. Eudy, J.D.; Weston, M.D.; Yao, S.; Hoover, D.M.; Rehm, H.L.; Ma-Edmonds, M.; Yan, D.; Ahmad, I.; Cheng, J.J.; Ayuso, C.; et al. Mutation of a gene encoding a protein with extracellular matrix motifs in usher syndrome type IIa. *Science (N. Y.)* **1998**, *280*, 1753–1757. [[CrossRef](#)]
23. Rivolta, C.; Sweklo, E.A.; Berson, E.L.; Dryja, T.P. Missense mutation in the *USH2A* gene: Association with recessive retinitis pigmentosa without hearing loss. *Am. J. Hum. Genet.* **2000**, *66*, 1975–1978. [[CrossRef](#)] [[PubMed](#)]
24. Estrada-Cuzcano, A.I.; Koenekoop, R.K.; Senechal, A.; De Baere, E.B.; de Ravel, T.; Banfi, S.; Kohl, S.; Ayuso, C.; Sharon, D.; Hoyng, C.B.; et al. *BBS1* mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to bardet-biedl syndrome. *Arch. Ophthalmol. (Chic. IL 1960)* **2012**, *130*, 1425–1432. [[CrossRef](#)] [[PubMed](#)]
25. Mykytyn, K.; Nishimura, D.Y.; Searby, C.C.; Shastri, M.; Yen, H.J.; Beck, J.S.; Braun, T.; Streb, L.M.; Cornier, A.S.; Cox, G.F.; et al. Identification of the gene (*BBS1*) most commonly involved in bardet-biedl syndrome, a complex human obesity syndrome. *Nat. Genet.* **2002**, *31*, 435–438. [[CrossRef](#)] [[PubMed](#)]
26. Katsanis, N.; Ansley, S.J.; Badano, J.L.; Eichers, E.R.; Lewis, R.A.; Hoskins, B.E.; Scambler, P.J.; Davidson, W.S.; Beales, P.L.; Lupski, J.R. Triallelic inheritance in bardet-biedl syndrome, a mendelian recessive disorder. *Science (N. Y.)* **2001**, *293*, 2256–2259. [[CrossRef](#)] [[PubMed](#)]
27. Den Hollander, A.I.; Koenekoop, R.K.; Yzer, S.; Lopez, I.; Arends, M.L.; Voeselek, K.E.; Zonneveld, M.N.; Strom, T.M.; Meitinger, T.; Brunner, H.G.; et al. Mutations in the *CEP290* (*NPHP6*) gene are a frequent cause of Leber congenital amaurosis. *Am. J. Hum. Genet.* **2006**, *79*, 556–561. [[CrossRef](#)] [[PubMed](#)]
28. Sayer, J.A.; Otto, E.A.; O’Toole, J.F.; Nurnberg, G.; Kennedy, M.A.; Becker, C.; Hennies, H.C.; Helou, J.; Attanasio, M.; Fausett, B.V.; et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. *Nat. Genet.* **2006**, *38*, 674–681. [[CrossRef](#)] [[PubMed](#)]
29. Valente, E.M.; Silhavy, J.L.; Brancati, F.; Barrano, G.; Krishnaswami, S.R.; Castori, M.; Lancaster, M.A.; Boltshauser, E.; Boccone, L.; Al-Gazali, L.; et al. Mutations in *CEP290*, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat. Genet.* **2006**, *38*, 623–625. [[CrossRef](#)] [[PubMed](#)]
30. Frank, V.; den Hollander, A.I.; Bruchle, N.O.; Zonneveld, M.N.; Nurnberg, G.; Becker, C.; Du Bois, G.; Kendziorra, H.; Roosing, S.; Senderek, J.; et al. Mutations of the *CEP290* gene encoding a centrosomal protein cause Meckel-Gruber syndrome. *Hum. Mutat.* **2008**, *29*, 45–52. [[CrossRef](#)] [[PubMed](#)]
31. Chiang, P.W.; Wang, J.; Chen, Y.; Fu, Q.; Zhong, J.; Chen, Y.; Yi, X.; Wu, R.; Gan, H.; Shi, Y.; et al. Exome sequencing identifies *NMNAT1* mutations as a cause of Leber congenital amaurosis. *Nat. Genet.* **2012**, *44*, 972–974. [[CrossRef](#)] [[PubMed](#)]
32. Koenekoop, R.K.; Wang, H.; Majewski, J.; Wang, X.; Lopez, I.; Ren, H.; Chen, Y.; Li, Y.; Fishman, G.A.; Genead, M.; et al. Mutations in *NMNAT1* cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. *Nat. Genet.* **2012**, *44*, 1035–1039. [[CrossRef](#)] [[PubMed](#)]
33. Perrault, I.; Hanein, S.; Zanlonghi, X.; Serre, V.; Nicouveau, M.; Defoort-Delhemmes, S.; Delphin, N.; Fares-Taie, L.; Gerber, S.; Xerri, O.; et al. Mutations in *NMNAT1* cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. *Nat. Genet.* **2012**, *44*, 975–977. [[CrossRef](#)] [[PubMed](#)]
34. Falk, M.J.; Zhang, Q.; Nakamaru-Ogiso, E.; Kannabiran, C.; Fonseca-Kelly, Z.; Chakarova, C.; Audo, I.; Mackay, D.S.; Zeitz, C.; Borman, A.D.; et al. *NMNAT1* mutations cause Leber congenital amaurosis. *Nat. Genet.* **2012**, *44*, 1040–1045. [[CrossRef](#)] [[PubMed](#)]
35. Siemiatkowska, A.M.; Schuurs-Hoeijmakers, J.H.; Bosch, D.G.; Boonstra, F.N.; Riemsdag, F.C.; Ruiters, M.; de Vries, B.B.; den Hollander, A.I.; Collin, R.W.; Cremers, F.P. Nonpenetrance of the most frequent autosomal recessive Leber congenital amaurosis mutation in *NMNAT1*. *JAMA Ophthalmol.* **2014**, *132*, 1002–1004. [[CrossRef](#)] [[PubMed](#)]
36. Valle, D.; Kaiser-Kupfer, M.I.; Del Valle, L.A. Gyrate atrophy of the choroid and retina: Deficiency of ornithine aminotransferase in transformed lymphocytes. *Proc. Natl. Acad. Sci. USA* **1977**, *74*, 5159–5161. [[CrossRef](#)] [[PubMed](#)]
37. Mitchell, G.A.; Brody, L.C.; Looney, J.; Steel, G.; Suchanek, M.; Dowling, C.; Der Kaloustian, V.; Kaiser-Kupfer, M.; Valle, D. An initiator codon mutation in ornithine-delta-aminotransferase causing gyrate atrophy of the choroid and retina. *J. Clin. Investig.* **1988**, *81*, 630–633. [[CrossRef](#)] [[PubMed](#)]
38. McWilliam, P.; Farrar, G.J.; Kenna, P.; Bradley, D.G.; Humphries, M.M.; Sharp, E.M.; McConnell, D.J.; Lawler, M.; Sheils, D.; Ryan, C.; et al. Autosomal dominant retinitis pigmentosa (ADRP): Localization of an *ADRP* gene to the long arm of chromosome 3. *Genomics* **1989**, *5*, 619–622. [[CrossRef](#)]

39. Bandah-Rozenfeld, D.; Mizrahi-Meissonnier, L.; Farhy, C.; Obolensky, A.; Chowers, I.; Pe'er, J.; Merin, S.; Ben-Yosef, T.; Ashery-Padan, R.; Banin, E.; et al. Homozygosity mapping reveals null mutations in *FAM161A* as a cause of autosomal-recessive retinitis pigmentosa. *Am. J. Hum. Genet.* **2010**, *87*, 382–391. [[CrossRef](#)] [[PubMed](#)]
40. Collin, R.W.; van den Born, L.I.; Klevering, B.J.; de Castro-Miro, M.; Littink, K.W.; Arimadyo, K.; Azam, M.; Yazar, V.; Zonneveld, M.N.; Paun, C.C.; et al. High-resolution homozygosity mapping is a powerful tool to detect novel mutations causative of autosomal recessive RP in the dutch population. *Investig. Ophthalmol. Vis. Sci.* **2011**, *52*, 2227–2239. [[CrossRef](#)] [[PubMed](#)]
41. Collin, R.W.; Littink, K.W.; Klevering, B.J.; van den Born, L.I.; Koenekoop, R.K.; Zonneveld, M.N.; Blokland, E.A.; Strom, T.M.; Hoyng, C.B.; den Hollander, A.I.; et al. Identification of a 2 Mb human ortholog of *Drosophila* eyes shut/spacemaker that is mutated in patients with retinitis pigmentosa. *Am. J. Hum. Genet.* **2008**, *83*, 594–603. [[CrossRef](#)] [[PubMed](#)]
42. Audo, I.; Bujakowska, K.M.; Leveillard, T.; Mohand-Said, S.; Lancelot, M.E.; Germain, A.; Antonio, A.; Michiels, C.; Saraiva, J.P.; Letexier, M.; et al. Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases. *Orphanet J. Rare Dis.* **2012**, *7*, 8. [[CrossRef](#)] [[PubMed](#)]
43. Nikopoulos, K.; Gilissen, C.; Hoischen, A.; van Nouhuys, C.E.; Boonstra, F.N.; Blokland, E.A.; Arts, P.; Wieskamp, N.; Strom, T.M.; Ayuso, C.; et al. Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. *Am. J. Hum. Genet.* **2010**, *86*, 240–247. [[CrossRef](#)] [[PubMed](#)]
44. Abu-Safieh, L.; Alrashed, M.; Anazi, S.; Alkuraya, H.; Khan, A.O.; Al-Owain, M.; Al-Zahrani, J.; Al-Abdi, L.; Hashem, M.; Al-Tarimi, S.; et al. Autozygome-guided exome sequencing in retinal dystrophy patients reveals pathogenetic mutations and novel candidate disease genes. *Genome Res.* **2013**, *23*, 236–247. [[CrossRef](#)] [[PubMed](#)]
45. Audo, I.; Bujakowska, K.; Orhan, E.; Poloschek, C.M.; Defoort-Dhellemmes, S.; Drumare, I.; Kohl, S.; Luu, T.D.; Lecompte, O.; Zrenner, E.; et al. Whole-exome sequencing identifies mutations in *gpr179* leading to autosomal-recessive complete congenital stationary night blindness. *Am. J. Hum. Genet.* **2012**, *90*, 321–330. [[CrossRef](#)] [[PubMed](#)]
46. Zeitz, C.; Jacobson, S.G.; Hamel, C.P.; Bujakowska, K.; Neuille, M.; Orhan, E.; Zanlonghi, X.; Lancelot, M.E.; Michiels, C.; Schwartz, S.B.; et al. Whole-exome sequencing identifies *LRIT3* mutations as a cause of autosomal-recessive complete congenital stationary night blindness. *Am. J. Hum. Genet.* **2013**, *92*, 67–75. [[CrossRef](#)] [[PubMed](#)]
47. Carss, K.J.; Arno, G.; Erwood, M.; Stephens, J.; Sanchis-Juan, A.; Hull, S.; Megy, K.; Grozeva, D.; Dewhurst, E.; Malka, S.; et al. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. *Am. J. Hum. Genet.* **2017**, *100*, 75–90. [[CrossRef](#)] [[PubMed](#)]
48. Haer-Wigman, L.; van Zelst-Stams, W.A.G.; Pfund, R.; van den Born, L.I.; Klaver, C.C.W.; Verheij, J.B.G.M.; Hoyng, C.B.; Breuning, M.H.; Boon, C.J.F.; Kievit, A.J.; et al. Diagnostic exome sequencing identifies a genetic cause in 50% of 266 Dutch patients with visual impairment. *Investig. Ophthalmol. Vis. Sci.* **2017**, *25*, 591–599.
49. Combs, R.; McAllister, M.; Payne, K.; Lowndes, J.; Devery, S.; Webster, A.R.; Downes, S.M.; Moore, A.T.; Ramsden, S.; Black, G.; et al. Understanding the impact of genetic testing for inherited retinal dystrophy. *Eur. J. Hum. Genet. EJHG* **2013**, *21*, 1209–1213. [[CrossRef](#)] [[PubMed](#)]
50. El Shamieh, S.; Neuille, M.; Terray, A.; Orhan, E.; Condroyer, C.; Demontant, V.; Michiels, C.; Antonio, A.; Boyard, F.; Lancelot, M.E.; et al. Whole-exome sequencing identifies *KIZ* as a ciliary gene associated with autosomal-recessive rod-cone dystrophy. *Am. J. Hum. Genet.* **2014**, *94*, 625–633. [[CrossRef](#)] [[PubMed](#)]
51. Bujakowska, K.M.; Fernandez-Godino, R.; Place, E.; Consugar, M.; Navarro-Gomez, D.; White, J.; Bedoukian, E.C.; Zhu, X.; Xie, H.M.; Gai, X.; et al. Copy-number variation is an important contributor to the genetic causality of inherited retinal degenerations. *Genet. Med.* **2017**, *19*, 643–651. [[CrossRef](#)] [[PubMed](#)]
52. Eisenberger, T.; Neuhaus, C.; Khan, A.O.; Decker, C.; Preising, M.N.; Friedburg, C.; Bieg, A.; Gliem, M.; Charbel Issa, P.; Holz, F.G.; et al. Increasing the yield in targeted next-generation sequencing by implicating cnv analysis, non-coding exons and the overall variant load: The example of retinal dystrophies. *PLoS ONE* **2013**, *8*, e78496. [[CrossRef](#)] [[PubMed](#)]

53. Bainbridge, J.W.; Smith, A.J.; Barker, S.S.; Robbie, S.; Henderson, R.; Balaggan, K.; Viswanathan, A.; Holder, G.E.; Stockman, A.; Tyler, N.; et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N. Engl. J. Med.* **2008**, *358*, 2231–2239. [[CrossRef](#)] [[PubMed](#)]
54. Hauswirth, W.W.; Aleman, T.S.; Kaushal, S.; Cideciyan, A.V.; Schwartz, S.B.; Wang, L.; Conlon, T.J.; Boye, S.L.; Flotte, T.R.; Byrne, B.J.; et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. *Hum. Gene Ther.* **2008**, *19*, 979–990. [[CrossRef](#)] [[PubMed](#)]
55. Maguire, A.M.; Simonelli, F.; Pierce, E.A.; Pugh, E.N., Jr.; Mingozzi, F.; Bennicelli, J.; Banfi, S.; Marshall, K.A.; Testa, F.; Surace, E.M.; et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N. Engl. J. Med.* **2008**, *358*, 2240–2248. [[CrossRef](#)] [[PubMed](#)]
56. Russell, S.; Bennett, J.; Wellman, J.A.; Chung, D.C.; Yu, Z.F.; Tillman, A.; Wittes, J.; Pappas, J.; Elci, O.; McCague, S.; et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. *Lancet (Lond. Engl.)* **2017**, *390*, 849–860. [[CrossRef](#)]
57. MacLaren, R.E.; Groppe, M.; Barnard, A.R.; Cottrill, C.L.; Tolmachova, T.; Seymour, L.; Clark, K.R.; Durrant, M.J.; Cremers, F.P.; Black, G.C.; et al. Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. *Lancet (Lond. Engl.)* **2014**, *383*, 1129–1137. [[CrossRef](#)]
58. Edwards, T.L.; Jolly, J.K.; Groppe, M.; Barnard, A.R.; Cottrill, C.L.; Tolmachova, T.; Black, G.C.; Webster, A.R.; Lotery, A.J.; Holder, G.E.; et al. Visual acuity after retinal gene therapy for choroideremia. *N. Engl. J. Med.* **2016**, *374*, 1996–1998. [[CrossRef](#)] [[PubMed](#)]
59. Koenekoop, R.K.; Sui, R.; Sallum, J.; van den Born, L.I.; Ajlan, R.; Khan, A.; den Hollander, A.I.; Cremers, F.P.; Mendola, J.D.; Bittner, A.K.; et al. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: An open-label phase 1b trial. *Lancet (Lond. Engl.)* **2014**, *384*, 1513–1520. [[CrossRef](#)]
60. Scholl, H.P.; Moore, A.T.; Koenekoop, R.K.; Wen, Y.; Fishman, G.A.; van den Born, L.I.; Bittner, A.; Bowles, K.; Fletcher, E.C.; Collison, F.T.; et al. Safety and proof-of-concept study of oral QLT091001 in retinitis pigmentosa due to inherited deficiencies of retinal pigment epithelial 65 protein (RPE65) or lecithin:Retinol acyltransferase (LRAT). *PLoS ONE* **2015**, *10*, e0143846. [[CrossRef](#)] [[PubMed](#)]
61. Clinical Trials. Available online: <http://clinicaltrials.gov> (accessed on 17 March 2018).
62. Slijkerman, R.W.; Song, F.; Astuti, G.D.; Huynen, M.A.; van Wijk, E.; Stieger, K.; Collin, R.W. The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies. *Prog. Retin. Eye Res.* **2015**, *48*, 137–159. [[CrossRef](#)] [[PubMed](#)]
63. Sung, C.H.; Davenport, C.M.; Nathans, J. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. *J. Biol. Chem.* **1993**, *268*, 26645–26649. [[PubMed](#)]
64. Bujakowska, K.M.; Zhang, Q.; Siemiatkowska, A.M.; Liu, Q.; Place, E.; Falk, M.J.; Consugar, M.; Lancelot, M.E.; Antonio, A.; Lonjou, C.; et al. Mutations in IFT172 cause isolated retinal degeneration and bardet-biedl syndrome. *Hum. Mol. Genet.* **2015**, *24*, 230–242. [[CrossRef](#)] [[PubMed](#)]
65. Sangermano, R.; Khan, M.; Cornelis, S.S.; Richelle, V.; Albert, S.; Garanto, A.; Elmelik, D.; Qamar, R.; Lugtenberg, D.; van den Born, L.I.; et al. ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice site variants in stargardt disease. *Genome Res.* **2018**, *28*, 100–110. [[CrossRef](#)] [[PubMed](#)]
66. Sangermano, R.; Bax, N.M.; Bauwens, M.; van den Born, L.I.; De Baere, E.; Garanto, A.; Collin, R.W.; Goercham-Ramlal, A.S.; den Engelsman-van Dijk, A.H.; Rohrschneider, K.; et al. Photoreceptor progenitor mRNA analysis reveals exon skipping resulting from the ABCA4 c.5461-10T→C mutation in Stargardt disease. *Ophthalmology* **2016**, *123*, 1375–1385. [[CrossRef](#)] [[PubMed](#)]
67. Tucker, B.A.; Mullins, R.F.; Streb, L.M.; Anfinson, K.; Eyestone, M.E.; Kaalberg, E.; Riker, M.J.; Drack, A.V.; Braun, T.A.; Stone, E.M. Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate retinitis pigmentosa. *Elife* **2013**, *2*, e00824. [[CrossRef](#)] [[PubMed](#)]
68. Parfitt, D.A.; Lane, A.; Ramsden, C.M.; Carr, A.J.; Munro, P.M.; Jovanovic, K.; Schwarz, N.; Kanuga, N.; Muthiah, M.N.; Hull, S.; et al. Identification and correction of mechanisms underlying inherited blindness in human iPSC-derived optic cups. *Cell Stem Cell* **2016**, *18*, 769–781. [[CrossRef](#)] [[PubMed](#)]

69. Lukovic, D.; Artero Castro, A.; Delgado, A.B.; Bernal Mde, L.; Luna Pelaez, N.; Diez Lloret, A.; Perez Espejo, R.; Kamenarova, K.; Fernandez Sanchez, L.; Cuenca, N.; et al. Human iPSC derived disease model of MERTK-associated retinitis pigmentosa. *Sci. Rep.* **2015**, *5*, 12910. [[CrossRef](#)] [[PubMed](#)]
70. Yoshida, T.; Ozawa, Y.; Suzuki, K.; Yuki, K.; Ohyama, M.; Akamatsu, W.; Matsuzaki, Y.; Shimmura, S.; Mitani, K.; Tsubota, K.; et al. The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa. *Mol. Brain* **2014**, *7*, 45. [[CrossRef](#)] [[PubMed](#)]
71. Albert, S.; Garanto, A.; Sangermano, R.; Khan, M.; Bax, N.M.; Hoyng, C.B.; Zernant, J.; Lee, W.; Allikmets, R.; Collin, R.W.J.; et al. Identification and rescue of splice defects caused by two neighboring deep-intronic ABCA4 mutations underlying stargardt disease. *Am. J. Hum. Genet.* **2018**, *102*, 517–527. [[CrossRef](#)] [[PubMed](#)]
72. Peng, Y.Q.; Tang, L.S.; Yoshida, S.; Zhou, Y.D. Applications of CRISPR/CAS9 in retinal degenerative diseases. *Int. J. Ophthalmol.* **2017**, *10*, 646–651. [[PubMed](#)]
73. Li, P.; Kleinstiver, B.P.; Leon, M.Y.; Prew, M.S.; Navarro-Gomez, D.; Greenwald, S.H.; Pierce, E.A.; Joung, J.K.; Liu, Q. Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa. *CRISPR J.* **2018**, *1*. [[CrossRef](#)]
74. Kajiwara, K.; Berson, E.; Dryja, T. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. *Science (N. Y.)* **1994**, *264*, 1604–1608. [[CrossRef](#)]
75. Beales, P.L.; Badano, J.L.; Ross, A.J.; Ansley, S.J.; Hoskins, B.E.; Kirsten, B.; Mein, C.A.; Froguel, P.; Scambler, P.J.; Lewis, R.A.; et al. Genetic interaction of BBS1 mutations with alleles at other BBS loci can result in non-Mendelian Bardet-Biedl syndrome. *Am. J. Hum. Genet.* **2003**, *72*, 1187–1199. [[CrossRef](#)] [[PubMed](#)]
76. Badano, J.L.; Leitch, C.C.; Ansley, S.J.; May-Simera, H.; Lawson, S.; Lewis, R.A.; Beales, P.L.; Dietz, H.C.; Fisher, S.; Katsanis, N. Dissection of epistasis in oligogenic Bardet-Biedl syndrome. *Nature* **2006**, *439*, 326–330. [[CrossRef](#)] [[PubMed](#)]
77. Vithana, E.N.; Abu-Safieh, L.; Pelosini, L.; Winchester, E.; Hornan, D.; Bird, A.C.; Hunt, D.M.; Bustin, S.A.; Bhattacharya, S.S. Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: A molecular clue for incomplete penetrance? *Investig. Ophthalmol. Vis. Sci.* **2003**, *44*, 4204–4209. [[CrossRef](#)]
78. Venturini, G.; Rose, A.M.; Shah, A.Z.; Bhattacharya, S.S.; Rivolta, C. CNOT3 is a modifier of PRPF31 mutations in retinitis pigmentosa with incomplete penetrance. *PLoS Genet.* **2012**, *8*, e1003040. [[CrossRef](#)] [[PubMed](#)]
79. Sobreira, N.; Schiettecatte, F.; Valle, D.; Hamosh, A. Genematcher: A matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* **2015**, *36*, 928–930. [[CrossRef](#)] [[PubMed](#)]
80. Genematcher. Available online: <https://genematcher.org/> (accessed on 17 March 2018).
81. ERDC Webpage. Available online: <http://www.erdcc.info/> (accessed on 17 March 2018).
82. Astuti, G.D.N.; van den Born, L.I.; Khan, M.I.; Hamel, C.P.; Bocquet, B.; Manes, G.; Quinodoz, M.; Ali, M.; Toomes, C.; McKibbin, M.; et al. Identification of inherited retinal disease-associated genetic variants in 11 candidate genes. *Genes* **2018**, *9*, 21. [[CrossRef](#)] [[PubMed](#)]
83. Nishiguchi, K.M.; Rivolta, C. Genes associated with retinitis pigmentosa and allied diseases are frequently mutated in the general population. *PLoS ONE* **2012**, *7*, e41902. [[CrossRef](#)] [[PubMed](#)]
84. Gustafson, K.; Duncan, J.L.; Biswas, P.; Soto-Hermida, A.; Matsui, H.; Jakubosky, D.; Suk, J.; Telenti, A.; Frazer, K.A.; Ayyagari, R. Whole Genome sequencing revealed mutations in two independent genes as the underlying cause of retinal degeneration in an Ashkenazi Jewish pedigree. *Genes* **2017**, *8*, 210. [[CrossRef](#)] [[PubMed](#)]
85. Llavona, P.; Pinelli, M.; Mutarelli, M.; Marwah, V.S.; Schimpf-Linzenbold, S.; Thaler, S.; Yoeruek, E.; Vetter, J.; Kohl, S.; Wissinger, B. Allelic Expression imbalance in the human retinal transcriptome and potential impact on inherited retinal diseases. *Genes* **2017**, *8*, 283. [[CrossRef](#)] [[PubMed](#)]
86. El Shamieh, S.; Méjécase, C.; Bertelli, M.; Terray, A.; Michiels, C.; Condroyer, C.; Fouquet, S.; Sadoun, M.; Clérin, E.; Liu, B.; et al. Further Insights into the ciliary gene and protein KIZ and its murine ortholog PLK1S1 Mutated in rod-cone dystrophy. *Genes* **2017**, *8*, 277. [[CrossRef](#)] [[PubMed](#)]
87. Dockery, A.; Stephenson, K.; Keegan, D.; Wynne, N.; Silvestri, G.; Humphries, P.; Kenna, P.F.; Carrigan, M.; Farrar, G.J. Target 5000: Target Capture sequencing for inherited retinal degenerations. *Genes* **2017**, *8*, 304. [[CrossRef](#)] [[PubMed](#)]
88. Comander, J.; Weigel-DiFranco, C.; Maher, M.; Place, E.; Wan, A.; Harper, S.; Sandberg, M.A.; Navarro-Gomez, D.; Pierce, E.A. The Genetic basis of pericentral retinitis pigmentosa—A Form of mild retinitis pigmentosa. *Genes* **2017**, *8*, 256. [[CrossRef](#)] [[PubMed](#)]

89. Di Iorio, V.; Karali, M.; Brunetti-Pierri, R.; Filippelli, M.; Di Fruscio, G.; Pizzo, M.; Mutarelli, M.; Nigro, V.; Testa, F.; Banfi, S.; Simonelli, F. Clinical and Genetic evaluation of a cohort of pediatric patients with severe inherited retinal dystrophies. *Genes* **2017**, *8*, 280. [[CrossRef](#)] [[PubMed](#)]
90. Porto, F.B.O.; Jones, E.M.; Branch, J.; Soens, Z.T.; Maia, I.M.; Sena, I.F.G.; Sampaio, S.A.M.; Simões, R.T.; Chen, R. Molecular Screening of 43 brazilian families diagnosed with leber congenital amaurosis or early-onset severe retinal dystrophy. *Genes* **2017**, *8*, 355. [[CrossRef](#)] [[PubMed](#)]
91. Brandl, C.; Schulz, H.L.; Charbel Issa, P.; Birtel, J.; Bergholz, R.; Lange, C.; Dahlke, C.; Zobor, D.; Weber, B.H.F.; Stöhr, H. Mutations in the Genes for interphotoreceptor matrix proteoglycans, *IMPG1* and *IMPG2*, in Patients with vitelliform macular lesions. *Genes* **2017**, *8*, 170. [[CrossRef](#)] [[PubMed](#)]
92. McGuigan, D.B.; Heon, E.; Cideciyan, A.V.; Ratnapriya, R.; Lu, M.; Sumaroka, A.; Roman, A.J.; Batmanabane, V.; Garafalo, A.V.; Stone, E.M.; et al. *EYS* Mutations causing autosomal recessive retinitis pigmentosa: Changes of Retinal structure and function with disease progression. *Genes* **2017**, *8*, 178. [[CrossRef](#)] [[PubMed](#)]
93. Roosing, S.; Cremers, F.P.M.; Riemsdag, F.C.C.; Zonneveld-Vrieling, M.N.; Talsma, H.E.; Klessens-Godfroy, F.J.M.; den Hollander, A.I.; van den Born, L.I. A Rare form of retinal dystrophy caused by hypomorphic nonsense mutations in *CEP290*. *Genes* **2017**, *8*, 208. [[CrossRef](#)] [[PubMed](#)]
94. Tracawska-Siemiatkowska, A.; Haer-Wigman, L.; Bosch, D.G.M.; Nickerson, D.; Bamshad, M.J.; University of Washington Center for Mendelian Genomics; van de Vorst, M.; Rendtorff, N.D.; Möller, C.; Kjellström, U.; et al. An Expanded multi-organ disease phenotype associated with mutations in *YARS*. *Genes* **2017**, *8*, 381. [[CrossRef](#)] [[PubMed](#)]
95. Littink, K.W.; Stappers, P.T.Y.; Riemsdag, F.C.C.; Talsma, H.E.; van Genderen, M.M.; Cremers, F.P.M.; Collin, R.W.J.; van den Born, L.I. Autosomal recessive *NRL* Mutations in patients with enhanced S-Cone Syndrome. *Genes* **2018**, *9*, 68. [[CrossRef](#)] [[PubMed](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).